ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Correvio receives FDA complete response letter for anti-arrhythmic drug Brinavess
December 25, 2019Correvio Pharma announced Tuesday that the FDA issued a complete response letter regarding its filing seeking approval of Brinavess (vernakalant) for the rapid conversion of recent-onset atrial fibrillation in adults, sending shares down as much as 12%.
Pharma Sources Insight January 2025
